Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 26Colorectal Neoplasms 6Recurrence 5Liver Neoplasms 4Cholangiocarcinoma 3Secondary Malignant Neoplasm of Liver 1Reperfusion Injury 1Postoperative Complications 1Pancreatic Neoplasms 1Obesity, Morbid 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Metabolic Syndrome 1Klatskin Tumor 1Disseminated Pancreatic Cancer 1Disease Progression 1Conversion Disorder 1Colonic Neoplasms 1Abdominal Injuries 1

Interventions

Gemcitabine 677130-nm albumin-bound paclitaxel 197Fluorouracil 184Oxaliplatin 173Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 129Irinotecan 111Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 71Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 48Magnetic Resonance Spectroscopy 45folfirinox 42Docetaxel 41Cetuximab 40irinotecan sucrosofate 36Specimen Handling 36S 1 (combination) 36Biopsy 30Radiation 29Paclitaxel 29Ipilimumab 27Surgical Procedures, Operative 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × Hepatectomy × Clear all
NCT03801915 2023-03-21

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡